Anti-neurodegeneration agent 1 |
| Katalog-Nr.GC31244 |
Anti-Neurodegenerationsmittel 1, eine auf Neurodegeneration gerichtete Verbindung, extrahiert aus dem Patent WO2008039514A1, Verbindung I.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 289893-23-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I.
In Anti-neurodegeneration agent 1 (Compound I)-treated mSODl(G93A) mice, Western blot analysis reveals an observable 'band shift' of HSF-I, indicative of a stress-induced activation of HSF-I by hyper-phosphorylation. Immunostaining reveals that, at 120 days of age, expression of Hsp70 and Hsp90 is increased in the lumbar spinal cords of both untreated and Anti-neurodegeneration agent 1- treated SOD1(G93A) mice, although there is a clear increase in the intensity of Hsp70 and Hsp90 immunoreactivity in motor neurons of Anti-neurodegeneration agent 1-treated mSODl(G93A) mice. Anti-neurodegeneration agent I- treated mice live an average of 153 days (±2.6 SEM, n=7). This represents a significant increase in lifespan of over 22% (p=
[1]. BARBER, Jack R. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH NEURODEGENERATION. WO2008039514A1.
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *